Skip to main content

Table 2 Clinical and parasitological outcomes

From: Implementation and evaluation of a quality and safety tool for ambulatory strongyloidiasis patients at high risk of adverse outcome

 

Pre-implementation (n = 26)

Post-implementation (n = 11)

p-value

Seroreversionc (%)

 Yes

8 (42.1)

5 (62.5)

 

 No

11 (57.9)

3 (37.5)a

0.420

Clearance of Stool larval shedding (%)

 Yes

4 (80.0)

3 (100.0)

 

 No

1 (20.0)

0 (0)

1.000

Loss to follow-up (%)

 Yes

6 (23.1)

2 (20.0)

 

 No

20 (76.9)

8 (80.0)b

1.000

  1. aOne patient not assessible
  2. bOne patient not assessible
  3. cdefined as a two-thirds reduction in baseline serologic optical density